Amicus Therapeutics - חוב לטווח קצר של החברה FOLD

Short-term debt of up to one year on the GURU.Markets chart is supported by a stable staff of R&D experts retained through stock options. Amicus Therapeutics (FOLD) generates revenue through the supply of high-cost drugs for patients with Pompe and Fabry diseases via insurance funds. The value of 0.00 is established as the baseline, which, coupled with expanding Galafold sales and a strong pipeline, is driving the company toward net profit.

An investment audit of Amicus Therapeutics (FOLD) requires an analysis of liabilities maturing within one year, which measure current liquidity and the risk of capital shortages. Monitoring the short-term debt portfolio on GURU.Markets allows for a comparison of the financial burden against the high stability of revenue from rare disease therapies, turning this indicator into a marker of business resilience in the face of debt payments.